Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced that it will host a live conference call and
audio webcast on Friday, November 13, 2020 at 8:30 a.m. ET to
report financial results for the third quarter ended September 30,
2020 and to provide a business overview.
To access the live conference call, please call (844) 815-4963
(domestic) or (210) 229-8838 (international) at least five minutes
prior to the start time and refer to conference ID 5878804. A live
audio webcast of the call will also be available on the
Presentations section of the Company’s website,
www.biopathholdings.com. An archived webcast will be available on
the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s lead product candidate, prexigebersen
(BP1001, targeting the Grb2 protein), is in a Phase 2 study for
blood cancers and prexigebersen-A, a drug product modification of
prexigebersen, is under consideration by the FDA to commence Phase
1 studies in solid tumors. This is followed by BP1002, targeting
the Bcl-2 protein, where it will be evaluated in lymphoma and solid
tumors clinical studies. For more information, please visit the
Company's website at http://www.biopathholdings.com.
Will O’ConnorStern Investor Relations
Doug Morris Investor Relations Bio-Path Holdings, Inc.